五种光子放疗设备在胰腺癌立体定向放疗中剂量学比较

doi:10.3760/cma.j.cn113030-20190606-00214

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To compare the dose distribution among CyberKnife, Tomotherapy, Edge, Triology and γ-knife in stereotactic body radiation therapy (SBRT) for pancreatic cancer. Methods Clinical data of 10 panreatic cancer patients receiving CyberKinife treatment were retrospectively analyzed. The treatment plans were designed by five apparatuses from five centers according to the uniform requirement. All plans were transferred to MIM system for the extraction of parameters, which mainly included Dmin, Dmean and Dmax of PTV, conformity index (CI), new conformity index (nCI), homogeneity index (HI), gradient index (GI), coverage, Dmax and dose-volume of the stomach and bowel. Results The best CI and nCI were obtained in Triology (P<0.001), and the worst HI was found in γ-knife (P<0.001). The best GI was found in CyberKnife, followed by γ-knife and Tomotherapy, and Edge showed the worst GI (P<0.001). The highest Dmin of PTV was found in both Edge and Triology, while lower Dmin of PTV was found in CyberKnife and Tomotherapy (P<0.001). Additionally, γ-knife provided the highest Dmean and Dmax of PTV (P<0.001). Regarding the organs at risk, the lowest Dmax and D5cm³ of the bowel (P<0.001), Dmax of the stomach (P=0.003), Dmax(P=0.001), D5cm³ (P<0.001) and D10cm³ (P=0.005) of the duodenum, Dmax(P<0.001) and D0.35cm³ (P<0.001) of the spinal cord were found in CyberKnife. The highest Dmax of the bowel was found in γ-knife. Furthermore, the highest D5cm³ of the duodenum was demonstrated in Edge (P<0.001) and Tomotherapy provided the highest Dmax(P<0.001) and D0.35cm³ of the spinal cord (P<0.001). Conclusions All five radiotherapy apparatuses can meet the requirement of SBRT for pancreatic cancer. More rapid dose fall-off could be obtained via CyberKnife and γ-knife. Triology and Edge provide better target conformity. CyberKnife can better protect the gastrointestinal tract.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Cao Yangsen
	Zhang Jianying
	Li Tingting
	Qiu Jianjian
	Zhang Libo
	Zhuang Yayun
	Su Yang
	Guo Xiaojing
	Zhang Huojun

Key words： CyberKnife Tomotherapy Linear accelerator γ-knife Dose distribution Pancreatic neoplasm/stereotactic body radiotherapy

Received: 06 June 2019

Fund:National Key Research and Development Project (2017YFC0113104)

Corresponding Authors: Zhang Huojun, Email:chyyzhj@163.com

Cite this article:

Cao Yangsen,Zhang Jianying,Li Tingting et al. Comparison of dose distributions among five radiotherapy apparatuses in stereotactic body radiation therapy for pancreatic cancer SBRT Group of Radiation Oncology Committee of Shanghai Medical Association[J]. Chinese Journal of Radiation Oncology, 2021, 30(2): 156-163.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20190606-00214 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I2/156

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492.
[2] Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer[J]. J Clin Oncol, 2009, 27(11):1806-1813. DOI:10.1200/JCO.2008.17.7188.
[3] Qing SW, Ju XP, Cao YS, et al. Dose escalation of stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with cyberknife:protocol of a phase I study[J]. Radiat Oncol, 2017, 12(1):6. DOI:10.1186/s13014-016-0760-1.
[4] Zhu X, Ju X, Fei C, et al. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial:study design and rationale of a phase Ⅱ clinical trial[J]. BMJ Open, 2016, 6(12):e013220. DOI:10.1136/bmjopen-2016-013220.
[5] Zhu X, Li F, Ju X, et al. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer[J]. Cancer Med, 2017, 6(10):2263-2270. DOI:10.1002/cam4.1164.
[6] Ozhasoglu C, Saw CB, Chen H, et al. Synchrony—cyberknife respiratory compensation technology[J]. Med Dosim, 2008, 33(2):117-123. DOI:10.1016/j.meddos.2008.02.004.
[7] Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy:the report of AAPM task group 101[J]. Med Phys, 2010, 37(8):4078-4101. DOI:10.1118/1.3438081.
[8] Li J, Galvin J, Harrison A, et al. Dosimetric verification using monte carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2012, 84(2):508-513. DOI:10.1016/j.ijrobp.2011.12.005.
[9] Li T, Ozhasoglu C, Burton S, et al. A method to improve dose gradient for robotic radiosurgery[J]. J Appl Clin Med Phys, 2015, 16(6):333-339. DOI:10.1120/jacmp.v16i6.5748.
[10] Kannarunimit D, Descovich M, Garcia A, et al. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors:a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy[J]. Technol Cancer Res Treat, 2015, 14(1):49-60. DOI:10.7785/tcrt.2012.500394.
[11] Aljabab S, Vellayappan B, Vandervoort E, et al. Comparison of four techniques for spine stereotactic body radiotherapy:dosimetric and efficiency analysis[J]. J Appl Clin Med Phys, 2018, 19(2):160-167. DOI:10.1002/acm2.12271.
[12] Yang J, Ma L, Wang XS, et al. Dosimetric evaluation of 4 different treatment modalities for curative-intent stereotactic body radiation therapy for isolated thoracic spinal metastases[J]. Med Dosim, 2016, 41(2):105-112. DOI:10.1016/j.meddos.2015.10.003.
[13] $\hat{S}$Blosarek K, Osewski W, Grządziel A, et al. Integral dose:comparison between four techniques for prostate radiotherapy[J]. Rep Pract Oncol Radiother, 2014, 20(2):99-103. DOI:10.1016/j.rpor.2014.10.010.
[14] Cao H, Xiao Z, Zhang Y, et al. Dosimetric comparisons of different hypofractionated stereotactic radiotherapy techniques in treating intracranial tumors> 3 cm in longest diameter[J]. J Neurosurg, 2019, 22(1):1-9. DOI:10.3171/2018.12. JNS181578.
[15] Lee SW, Jang S, Pyakuryal AP, et al. The impact of CyberKnife′s prescription isodose percentage on intracranial target planning[J]. J Appl Clin Med Phys, 2014, 15(5):278-280. DOI:10.1120/jacmp.v15i5.5081.
[16] Xu Q, Fan J, Grimm J, et al. The dosimetric impact of the prescription isodose line (IDL) on the quality of robotic stereotactic radiosurgery (SRS) plans[J]. Med Phys, 2017, 44(12):6159-6165. DOI:10.1002/mp.12630.
[17] Sahgal A, Barani IJ, Jr NJ, et al. Prescription dose guideline based on physical criterion for multiple metastatic brain tumors treated with stereotactic radiosurgery[J]. Int J Radiat Oncol, 2010, 78(2):605-608. DOI:10.1016/j.ijrobp.2009.11.055.
[18] Jia F, Xu D, Yue H, et al. Comparison of flattening filter and flattening filter-free volumetric modulated arc radiotherapy in patients with locally advanced nasopharyngeal carcinoma[J]. Med Sci Monit, 2018, 24:8500-8505. DOI:10.12659/MSM.910218.
[19] Kumar L, Yadav G, Samuvel KR, et al. Dosimetric influence of filtered and flattening filter free photon beam on rapid arc (RA) radiotherapy planning in case of cervix carcinoma[J]. Rep Pract Oncol Radiother, 2017, 22(1):10-18. DOI:10.1016/j.rpor.2016.09.010.
[20] Sun WZ, Chen L, Yang X, et al. Comparison of treatment plan quality of VMAT for esophageal carcinoma with:flattening filter beam versus flattening filter free beam[J]. J Cancer, 2018, 9(18):3263-3268. DOI:10.7150/jca.26044.